Free Trial
NASDAQ:ZURA

Zura Bio Q4 2024 Earnings Report

Zura Bio logo
$1.18 -0.05 (-3.69%)
As of 12:13 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Zura Bio EPS Results

Actual EPS
-$0.08
Consensus EPS
-$0.17
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Zura Bio Revenue Results

Actual Revenue
$0.00 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Zura Bio Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Tuesday, March 25, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Zura Bio's Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Zura Bio Earnings Headlines

Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
Zura Bio price target lowered to $3 from $5 at H.C. Wainwright
Zura Bio (ZURA) Gets a Buy from Guggenheim
See More Zura Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zura Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zura Bio and other key companies, straight to your email.

About Zura Bio

Zura Bio (NASDAQ:ZURA), a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

View Zura Bio Profile

More Earnings Resources from MarketBeat